Key result
Combination antiplatelet therapy with aspirin and a thienopyridine improves clinical outcomes in patients with acute coronary syndromes and those undergoing PCI.
Why the study?
Does combination antiplatelet therapy with aspirin and a thienopyridine improve clinical outcomes in patients with acute coronary syndromes and those undergoing percutaneous coronary interventions?
Does combination antiplatelet therapy with aspirin and a thienopyridine improve clinical outcomes in patients with acute coronary syndromes and those undergoing percutaneous coronary interventions?
Answers are grounded in this paper and cite their sources.
Combination antiplatelet therapy with aspirin and a thienopyridine improves clinical outcomes in patients with ACS and those undergoing PCI, though optimal dosing and duration remain unknown.
Conclusion: The use of combination antiplatelet therapy with aspirin (ASA) and a thienopyridine has resulted in improved clinical outcomes in patients with acute coronary syndromes (ACS) and in those who undergo percutaneous coronary interventions (PCI). The most appropriate dose of thienopyridine therapy and its optimal duration of pretreatment and administration post-PCI remain unknown. ...
No takes yet. Share an insight, caveat, or question.
Braunwald et al. (2008) studied this question. Combination antiplatelet therapy with aspirin and a thienopyridine improves clinical outcomes in patients with acute coronary syndromes and those undergoing PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: